


I hereby certify that this correspondence (and any paper or fee referred to as being transmitted herewith) via first class mail in an envelope addressed to the COMMISSIONER FOR PATENTS, ALEXANDRIA, VIRGINIA 22313, on



November 18, 2003
(Date)

Travis Hill 11/18/03
(Signature and Date)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of:

Han et al.

: Art Unit : Unassigned

Serial No. : 10/654,770

: Examiner : Unassigned

Filed : August 21, 2003

Title : APPARATUS AND METHOD FOR
MEASURING A WEIGHT LOAD EXERTED :
BY A LEG OF A LAB ANIMAL OR A HUMAN :
BEING :

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. 1.97-1.99, applicants respectfully request that the following references be made of record in the above-identified application:

United States Patents

4,427,083
4,804,052
5,724,267
5,734,128
6,629,056 B2

Issued

January 24, 1984
February 14, 1989
March 3, 1998
March 31, 1998
September 30, 2003

Inventor(s)

Muddle
Griffen
Richards
Gades et al.
Han et al.

Other Documents

Larsen et al., "Reduction in Locomotor Activity of Arthritic Rats as Parameter for Chronic Pain : Effect of Morphine, Acetylsalicylic Acid and Citalopram," *Acta Pharmacol. Et Toxicol.*, 57:345-351 (1985).

Cain et al., "Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain," *Physiology & Behavior*, **62(1)**:199-205 (1997).

Hallas et al., "Establishment of Behavioral Parameters For The Evaluation of Osteopathic Treatment Principles in a Rat Model of Arthritis," *JAOA*, **97(4)**:207-214 (1997).

Sluka et al., "Differential Effects of N-Methyl-D-Aspartate (NMDA) and non-NMDA Receptor Antagonists on Spinal Release of Amino Acids After Development of Acute Arthritis In Rats," *Brain Research*, **664**:77-84 (1994).

Lawand et al., "Nicotinic Cholinergic Receptors : Potential Targets for Inflammatory Pain Relief," *Pain*, **80**:291-299, (1999).

Lu et al., "Gabapentin Attenuates Nociceptive Behaviors in an Acute Arthritis Model In Rats," *The Journal of Pharmacology and Experimental Therapeutics*, **290(1)**:214-219 (1999).

Okuda et al., "Arthritis Induced in Cat by Sodium Urate : A Possible Animal Model for Tonic Pain," *Pain*, **18**:287-297 (1984).

Clarke, K.A., "Differential Fore- and Hindpaw Force Transmission in the Walking Rat," *Physiology & Behavior*, **58(3)**:415-419 (1995).

Clarke et al., "Gait Analysis in a Rat Model of Osteoarthritis," *Physiology & Behavior*, **62(5)**:951-954 (1997).

Schott et al., "Weight Bearing as an Objective Measure of Arthritic Pain in the Rat," *Journal of Pharmacological and Toxicological Methods*, **31(2)**:79-83 (1994).

Copies of the aforementioned publications are submitted herewith along with a completed form PTO-1449. The references are listed on form PTO-1449.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56. The submission of references with this Information Disclosure Statement should not be construed by the Examiner that a comprehensive search through the prior art was conducted; it is requested that the Examiner make such a comprehensive search.

The above citations do not constitute an admission that the references are relevant or material to the claims; they are cited only as constituting the closest art of which applicant is aware. As such, it is respectfully submitted that the Claims presented for examination define patentable subject matter thereover. Favorable consideration on the merits is respectfully requested.


Correspondence and Fees

Please address all correspondence to Intellectual Property Docket Administrator, Gibbons, Del Deo, Dolan, Griffinger & Vecchione, One Riverfront Plaza, Newark, NJ 07102-5497. Telephone calls should be made to Livia Boyadjian at (973) 596-4825 and fax communications should be sent directly to her at (973) 639-8350.

Should any fees be required, please charge the required fee to Deposit Account No. 03-3839.

Thank you for your consideration.

Date: November 18, 2003



Livia Boyadjian
Attorney for Applicant
Registration No. 34,781

Gibbons, Del Deo, Dolan,
Griffinger & Vecchione
One Riverfront Plaza
Newark, New Jersey 07102



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/654,770
		Filing Date	August 21, 2003
		First Named Inventor	HAN, Hee-Chul
		Art Unit	Unassigned
Examiner Name	Unassigned		
Attorney Docket Number	102084-39581 CIP		
Sheet	1	of	2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 4,427,083	1-24-84	Muddle	
		US- 4,804,052	2-14-89	Griffen	
		US- 5,724,267	3-3-98	Richards	
		US- 5,734,128	3-31-98	Gades et al.	
		US- 6,629,056 B2	9-30-03	Han et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2		Complete if Known	
		Application Number	10/654,770
		Filing Date	August 21, 2003
		First Named Inventor	HAN, Hee-Chul
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	102084-39581 CIP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Larsen et al., "Reduction in Locomotor Activity of Arthritic Rats as Parameter for Chronic Pain: Effect of Morphine, Acetylsalicylic Acid and Citalopram," Acta Pharmacol. Et Toxicol., 57:345-351 (1985).	
		Cain et al., "Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain," Physiology & Behavior, 62(1):199-205 (1997).	
		Hallas et al., "Establishment of Behavioral Parameters for the Evaluation of Osteopathic Treatment Principles in a Rat Model of Arthritis," JAOA, 97(4):207-214 (1997).	
		Sluka et al. "Differential Effects of N-Methyl-D-Aspartate (NMDA) and non-NMDA Receptor Antagonists on Spinal Release of Amino Acids After Development of Acute Arthritis in Rats," Brain Research, 664:77-84 (1994).	
		Lawand et al., "Nicotinic Cholinergic Receptors: Potential Targets for Inflammatory Pain Relief," Pain, 80:291-299, (1999).	
		Lu et al., "Gabapentin Attenuates Nociceptive Behaviors in a Acute Arthritis Model in Rats," The Journal of Pharmacology and Experimental Therapeutics, 290(1):214-219 (1999).	
		Okuda et al., "Arthritis Induced in Cat by Sodium Urate: A possible Animal Model For Tonic Pain," Pain, 18:287-297 (1984).	
		Clarke, K.A., "Differential Fore-and Hindpaw Force Transmission in the Walking Rat," Physiology & Behavior, 58(3): 415-419 (1995).	
		Clarke et al., "Gait Analysis in a Rat Model of Osteoarthritis," Physiology & Behavior, 62(5):951-954 (1997).	
		Schott et al., "Weight Bearing as an Objective Measure of Arthritic Pain in the Rat," Journal of Pharmacological and Toxicological Methods, 31(2):79-83 (1994).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.